The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine. The study, published in eClinicalMedicine, details an international, multicenter phase 2/3 clinical trial that found a combination of amubarvimab and romlusevimab did not reduce the occurrence of long COVID symptoms.
Search continues for treatment that reduces long COVID symptoms: Study assesses ‘symptom diary’ of trial participants
Tech News
-
Free Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
Smart buildings: What happens to our free will when tech makes choices for us?
-
Screenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
Darknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
Privacy violations undermine the trustworthiness of the Tim Hortons brand
-
Why Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars